275 results on '"Ullmann, Andrew"'
Search Results
2. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
3. Impact of immunosuppressive and antifungal drugs on PBMC- and whole blood-based flow cytometric CD154+Aspergillus fumigatus specific T-cell quantification
4. Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT
5. Evaluation of Aspergillus and Mucorales specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure
6. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study
7. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
8. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
9. Clinical-scale isolation of the total Aspergillus fumigatus–reactive T–helper cell repertoire for adoptive transfer
10. The “Choosing Wisely” initiative in infectious diseases
11. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
12. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
13. Intra‐ and inter‐individual variability of Aspergillus fumigatus reactive T‐cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment
14. Impfen bei Immundefizienz
15. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology
16. Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
17. Estimated burden of fungal infections in Germany
18. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry
19. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
20. CMV Prophylaxis in Hematopoietic-Cell Transplantation
21. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
22. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species
23. Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
24. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation
25. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting
26. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole
27. Preface
28. Comparison of 2 studies of treatment of invasive aspergillosis
29. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
30. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial)
31. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
32. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and ≤106/kg T cells may have an adverse effect on transplant-related mortality
33. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections
34. Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report
35. Once-Daily Oral Levofloxacin Monotherapy versus Piperacillin/Tazobactam Three Times a Day: A Randomized Controlled Multicenter Trial in Patients with Febrile Neutropenia
36. Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation
37. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
38. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
39. Economic Evaluation of Voriconazole versus Conventional Amphotericin B in the Treatment of Invasive Aspergillosis in Germany
40. Safety of micafungin in prospective and retrospective clinical trials
41. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease
42. Posaconazole concentrations in the central nervous system
43. Nephrotoxicity in the setting of invasive fungal diseases
44. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis
45. Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease
46. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats
47. Posaconazole Prophylaxis in Hematologic Cancer
48. Posaconazole Prophylaxis in Hematologic Cancer
49. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
50. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.